
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has demonstrated robust growth potential with management guiding for 2025 global sales in the Neuroscience segment to reach approximately $10.7 billion, reflecting an increase attributable to various key products including Vyalev and Botox Therapeutic. The company's revised fiscal year 2025 earnings per share guidance has been raised to a range of $12.09 to $12.29, alongside a revenue forecast increase to roughly $59.7 billion, indicating strong underlying business performance. Notably, AbbVie reported first-quarter sales of $13.34 billion, surpassing expectations and showcasing the strong commercial success of their immunology and oncology franchises, underscoring their capacity for sustained growth moving forward.
Bears say
The analysis highlights several fundamental reasons for a negative outlook on AbbVie’s stock. Firstly, significant concerns exist regarding the company’s dependence on key products like Humira, which faces increasing biosimilar competition, coupled with disappointing market penetration of Rinvoq and Skyrizi, jeopardizing long-term revenue expectations in key therapeutic areas. Additionally, the Aesthetics segment is adversely impacted by macroeconomic challenges, further compounded by competitive pressures and potential setbacks in AbbVie’s drug pipeline, which could undermine the overall financial stability and growth prospects of the company.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares